# PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Source: https://onco.cc/trials/nct06788171/  
OnCo record `nct06788171` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab (glioblastoma use), capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and sintilimab in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.

## Summary

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM is a phase 2, interventional study registered as NCT06788171 by Fujian Cancer Hospital, with a registry enrolment figure of 35 participants, started 2025-03-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy; Bevacizumab; Capecitabine; Oxaliplatin; Sintilimab. Conditions listed: Colorectal Cancer Liver Metastasis. Primary outcome: Progression-free-Survival. Colorectal eligibility wording from the registry: "Pathologically confirmed colorectal cancer with liver metastases (stage M1)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06788171
- Phase: 2
- Setting: A Phase II Trial of PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy) Combined With PD-1 Ab and Chemotherapy Plus Bevacizumab for Colorectal Cancer Liver Metastasis
- Sponsor: Fujian Cancer Hospital
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT06788171: https://clinicaltrials.gov/study/NCT06788171

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06788171.json